Hospitals say the FDA and drugmakers should loop in hospitals and group purchasing organizations to attack drug shortages the way police would attack a hostage situation.
The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises. Pfizer and Merck, with ongoing patent issues and reorganizations, saw their positions fall a couple of notches, and AbbVie, having been spun off from Abbott Laboratories at the beginning of the year, didn't quite make the top 10. Its disappearance allowed Eli Lilly to make the list. It also helped Bayer HealthCare move up a couple of notches.
After the major patent crashes of 2012, last year was more of a transitional period. Johnson & Johnson, Novartis, Roche, GlaxoSmithKline, Eli Lilly and Bayer saw their revenues rise, although only J&J and Bayer had an appreciable change. Bayer's pharma revenues, combined with its consumer health unit, saw revenue growth of 7.6% based on dollars. J&J's number was up 6.7%, driven in large part by its pharma division. The others were flat or had growth of less than 3%. Read the full report in FiercePharma >>
Layoffs are always big news in pharma, as they are seen as an indicator of the health of the industry. Companies don't like to have to announce them, but when they decide to, getting plenty of attention becomes important. That is to impress upon investors that their CEOs are making the hard decisions needed to keep costs in line. Of course employees are interested. They know from the inside what is about to happen, and having lived through the awful anticipation, they want to see what the carnage is really going to be.
The patent cliff is often the big culprit. One might think that a one-to-one relationship could be graphed between what is happening with the patent cliff and layoffs, but that is not the case. Pharma analysis company EvaluatePharma has forecast that there were $41 billion in patent sales at risk in 2011, a year in which the top 10 pharma layoffs amounted to 26,500. In 2012, the peak year, EvalutePharma said a whopping $67 billion was at risk. In that year, the top layoffs tallied more than 34,600. Then in 2013, when at-risk sales fell to only $29 billion, we have a total for the top 10 of nearly 27,900. Read the report from FiercePharma >>
This is the best FiercePharma reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Have something to say? Join the conversation at
FiercePharma's LinkedIn group.
POPULAR COMMENT THREADS
GlaxoSmithKline, which is making big investments in manufacturing in the U.K., will help its homeland try to figure out how to revive its manufacturing base.
The FDA has held off approval of a new Eli Lilly diabetes drug until partner Boehringer Ingelheim fixes problems at a plant that last year was slapped with a warning letter.
Eli Lilly and Chinese partner Novast have started on a new plant in China to manufacture generic versions of Lilly drugs, a bit of good news on a day when manufacturing issues had otherwise cast a shadow over the Indianapolis-based drugmaker.
Baxter International, which has had ongoing contamination issues with some of its intravenous products, is now recalling one lot of a peritoneal product used on dialysis patients. It says the lot is contaminated with mold. The announcement, also sent out by the FDA, says there have been adverse reactions reported.
Sterile injectables maker Sagent Pharmaceuticals is recalling a product because of leaking bags. It is the second recall in about 9 months for the company, which relies mostly on contractors to manufacture its products.
The FDA placed an import ban on products from Ranbaxy Laboratories' active pharmaceutical plant in Toansa, India, in January, calling into question its drug analysis and sanitation. But there are other problems at the plant, like worker safety, that the FDA does not address and which get little attention from Indian authorities.
From Our Sister Sites
A British drugmaker has landed in the middle of the controversy over Sweetwater, Texas' Rattlesnake RoundUp
Here's what a successful negotiation with a government payer will get you: An 18% hike in your earnings forecast, about $150 million in additional sales, and a quick spike in share price. That's what Alexion yielded from a new reimbursement deal with France on its pricey rare disease treatment Soliris.